Manhard Kimberly's Form 4 filing
Heron Therapeutics, Inc. (HRTX) · filed May 4, 2022
- Accession no.
- 0001209191-22-027232
- Filed
- May 4, 2022
- Trade date
- Apr 29-May 3, 2022
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $7.16K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Manhard KimberlyCIK 0001202094 | Director, Officer (EVP, Drug Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 29, 2022 | Common Stock | JOtherAcquired | +1,504 | $3.84 | +$5,775.36 | 12,376 | Direct | |
| May 3, 2022 | Common Stock | SSaleDisposed | −1,504 | $4.76 | −$7,159.04 | 10,872 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.